Among patients initially diagnosed with pure autonomic failure, 12% progressed to develop central nervous system involvement, most commonly multiple system atrophy.
Cohort (n=318)
No
What are the predictors of progression from pure autonomic failure to other synucleinopathies?
Over 10% of patients initially diagnosed with pure autonomic failure eventually progress to central nervous system synucleinopathies, which can be predicted by specific clinical and autonomic variables.
OBJECTIVE: Based on the observation that a subset of patients originally diagnosed with pure autonomic failure (PAF) eventually develops extrapyramidal or cerebellar involvement consistent with multiple system atrophy (MSA), Parkinson disease (PD), or dementia with Lewy bodies (DLB), we aimed to identify predictors of progression of PAF to more sinister synucleinopathies. METHODS: In this retrospective cohort study, we reviewed patients seen at Mayo Clinic Rochester by autonomic specialists between 2001 and 2011 and during initial evaluation diagnosed with orthostatic hypotension consistent with PAF (possible PAF). In order to assess for the presence or absence of progression, we identified patients with 3 years or more of in-person follow-up (stable PAF) or documented progression to another synucleinopathy (converters). To identify predictors of conversion, we assessed odds of conversion based on clinical, autonomic, and laboratory variables. RESULTS: Among 318 patients fulfilling criteria for possible PAF, we identified 41 with stable PAF and 37 (12%) converters. Of those who evolved, 22 developed MSA, 11 developed PD/DLB, and 4 remained indeterminate. Several variables were identified to predict conversion to MSA: (1) mild degree of cardiovagal impairment, (2) preganglionic pattern of sweat loss, (3) severe bladder dysfunction, (4) supine norepinephrine >100 pg/mL, and (5) subtle motor signs at first presentation. Separate variables were found to predict conversion to PD/DLB. Composite conversion scores were generated based on individual predictors. CONCLUSIONS: Over 10% of patients originally diagnosed with PAF eventually evolve to develop CNS involvement, most commonly MSA. A combination of variables allows for prediction of conversion.
Singer et al. (Thu,) conducted a cohort in Pure autonomic failure (n=318). Clinical, autonomic, and laboratory variables (e.g., supine norepinephrine >100 pg/mL) vs. Absence of predictor variables was evaluated on Progression to another synucleinopathy (MSA, PD, or DLB). Among patients initially diagnosed with pure autonomic failure, 12% progressed to develop central nervous system involvement, most commonly multiple system atrophy.